Testing a new dose schedule of sacituzumab govitecan for advanced TNBC
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a different dose and schedule of the drug sacituzumab govitecan for people with advanced triple-negative breast cancer. It aims to see if this new approach is safer and more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have triple-negative breast cancer that has spread or cannot be removed by surgery.
- For Phase 1: You have already tried at least one chemotherapy that didn't work or stopped working.
- For Phase 2: You have not had any treatment for advanced breast cancer yet, and your tumor is PD-L1 negative (or you have received a checkpoint inhibitor or cannot take one).
- You have measurable tumors (can be seen on scans).
- You are in good general health (able to do light activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called sacituzumab govitecan for people with newly diagnosed triple-negative breast cancer (TNBC) that hasn't been treated yet. The drug targets cancer cells directly to try to stop them from growing.
This trial tests a two-drug combination (sacituzumab govitecan and pembrolizumab) versus sacituzumab govitecan alone before surgery for low-risk, triple-negative breast cancer that hasn't spread. The goal is to see which approach works better at shrinking tumors.
This trial tests sacituzumab govitecan (an antibody-drug medicine) with or without pembrolizumab (an immune-system therapy) in people with metastatic triple-negative breast cancer. It may help by shrinking tumors and improving immune control, especially for patients with specific tumor marker results.
This study compares a new combination of drugs (sacituzumab govitecan and pembrolizumab) against standard chemotherapy after you have already had initial chemotherapy. The aim is to see if the new combination shrink more breast cancers before surgery in people with triple-negative breast cancer.
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
This trial tests a new drug combination for people with advanced breast cancer (triple-negative or hormone receptor-positive). The goal is to see if the combination helps shrink tumors or slow their growth.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.